Skip to main content

Table 3 Factors contributing to Psychosocial Summary Score (PsS) in 60 patients with new-onset polyarticular juvenile idiopathic arthritis

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 

Univariate

Mixed Model

β (95% CI)/Mean PsS (95% CI)

p

β (95% CI)

p

Gender (mean)

 

<0.001

  

 Female

54.66 (53.78 to 55.54)

   

 Male

51.12 (49.98 to 53.27)

   

Time of visit (weeks)

 

0.036

  

 0

51.00 (49.10 to 52.90)

   

 6

52.02 (50.15 to 53.89)

   

 12

52.76 (50.89 to 54.63)

   

 24

53.81 (51.94 to 55.68)

   

 36

54.48 (52.58 to 56.38)

   

 48

54.70 (52.82 to 56.58)

   

 54

54.66 (52.77 to 56.54)

   

Age at onset

0.134 (-0.92 to 0.36)

0.245

  

Treatment (mean)

 

0.113

  

 IFX+ MTX

53.72 (52.4 to 55.0)

0.971a

  

 Triple

52.4 (51.1 to 53.5)

0.139b

  

 MTX

54.1 (52.8 to 55.3)

   

JADAS10

-0.251 (-0.378 to -0.125)

<0.001

-0.038 (-0.24 to 0.16)

0.701

Pain-VAS

-0.084 (-0.118 to -0.051)

<0.001

0.001 (-0.055 to 0.58)

0.96

Corticosteroid used

-0.005 (-0.014 to 0.003)

0.193

  

Time in remissione

0.009 (-0.035 to 0.054)

0.679

  

CHAQ

-5.710 (-7.117 to -4.303)

<0.001

-5.07 (-7.85 to -2.29)

<0.001

CHAQ*JADAS

  

-0.116 (-0.309 to 0.077)

0.237

CHAQ*Pain-VAS

  

0.047 (-0.011 to 0.105)

0.115

  1. For numerical factors, Coefficient beta indicated; for categorical values mean PsS value indicated.
  2. Sidak correction for multiple comparisons used. Factors with p-value <0.05 in univariate analyses were selected for multivariate mixed model. Values shown in Mixed Model column have been adjusted with other variables in the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate, hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, CHAQ child health assessment questionnaire, PsS Psychosocial summary Score. aIFX+MTX vs MTX; bTriple vs MTX; for IFX+MTX vs Triple p=0.318; dAmount of corticosteroids per body weight (intra-articular or oral) before individual study visit, adjusted for 6 weeks’ time (mg/kg); eCumulative time in remission since onset, *interaction term
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096